Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLZITAL vs BUTABARB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Sedation,Short-term treatment of insomnia,Management of seizure disorders (generalized tonic-clonic and partial seizures),Preoperative anxiety
Sedative,Hypnotic,Anticonvulsant,Preoperative anxiety
5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 8-12 hours in renal impairment.
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Primarily hepatic via CYP2C9, CYP2C19, and glucuronidation; metabolized to inactive metabolites (e.g., p-hydroxyphenobarbital) that are excreted renally.
Hepatic metabolism via CYP2C9 and CYP2C19; minor pathways involve glucuronidation.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other.
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
92% bound to albumin and alpha-1-acid glycoprotein.
Approximately 20-25% bound to plasma proteins (albumin).
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution.
0.5-0.6 L/kg in adults. Higher Vd suggests distribution into total body water and tissues; may increase in obesity.
Oral: 85-90% due to first-pass metabolism; intravenous: 100%.
Oral: 95-100% (well absorbed). Rectal: 80-90%. IM: 80-100%.
GFR 30-50 m L/min: 50% dose reduction; GFR <30 m L/min: avoid use.
e GFR 30-50 m L/min: reduce dose by 25%. e GFR <30 m L/min: avoid use or use 50% reduction with caution.
Child-Pugh Class B: 50% dose reduction; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
0.1-0.2 mg/kg orally every 4-6 hours as needed; maximum single dose 5 mg; not to exceed 20 mg per day.
0.5-1 mg/kg/dose orally every 6-8 hours; maximum 30 mg/dose. Not recommended for children under 6 years.
Initiate at 2.5 mg orally every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Initiate at 7.5-15 mg orally 2-3 times daily; increase slowly. Avoid in frail elderly. Monitor for paradoxical excitation.
Risk of respiratory depression, particularly with rapid IV administration or excessive doses; co-administration with CNS depressants (e.g., opioids, alcohol) may exacerbate this effect. Use in pregnancy may cause fetal harm (teratogenic effects).
May be habit forming; potential for abuse and dependence. Abrupt discontinuation may precipitate life-threatening withdrawal symptoms.
Respiratory depression, CNS depression, dependence and withdrawal (taper gradually), paradoxical excitation (especially in elderly), use in hepatic or renal impairment, drug interactions with warfarin, oral contraceptives, and corticosteroids.
Respiratory depression, especially when combined with other CNS depressants; tolerance and dependence; withdrawal seizures; use with caution in hepatic impairment and elderly.
Hypersensitivity to barbiturates, severe respiratory insufficiency, history of porphyria, severe hepatic impairment, pregnancy (especially first trimester).
Hypersensitivity to barbiturates, porphyria, severe respiratory insufficiency, history of substance abuse.
Avoid excessive alcohol consumption; may increase hepatotoxicity. No significant food interactions. Take with or without food; food may reduce GI upset.
Avoid grapefruit juice as it may inhibit metabolism and increase sedative effects. Take with food if gastrointestinal upset occurs. Limit caffeine intake as it may reduce sedative efficacy.
Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbiturate use may lead to neonatal withdrawal and coagulation defects due to vitamin K deficiency; use only if benefit outweighs risk.
Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, and cardiovascular anomalies. Second and third trimesters: Potential for fetal dependence, withdrawal syndrome, and impaired brain development. Chronic use may cause fetal growth restriction and preterm birth.
Butalbital and acetaminophen are excreted into breast milk in low amounts. Caffeine also enters milk. M/P ratio not established for butalbital. Use caution; monitor infant for sedation, poor feeding. American Academy of Pediatrics considers butalbital compatible with breastfeeding but avoid prolonged use.
Barbiturates are excreted into breast milk in low concentrations. M/P ratio is approximately 0.5-0.6. Chronic high-dose use may lead to infant sedation and difficulty feeding. Monitor infant for signs of drowsiness, lethargy, or poor suckling. Use caution, especially in neonates or preterm infants.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, hepatic metabolism) may reduce butalbital levels; clinical efficacy not well studied. Use lowest effective dose shortest duration. Acetaminophen doses remain standard (<4 g/day). Avoid caffeine >300 mg/day.
Pregnancy induces hepatic microsomal enzymes, increasing barbiturate metabolism. Higher doses (increased by 30-50%) may be required to maintain therapeutic levels. Monitor serum drug levels if needed, especially in third trimester. Postpartum, reduce dose to prepregnancy levels to avoid toxicity.
ALLZITAL is a combination analgesic containing acetaminophen and tramadol. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcohol intoxication. Maximum daily acetaminophen dose is 4000 mg; reduce in hepatic risk. Tramadol may lower seizure threshold; use cautiously in epilepsy. Not recommended in breastfeeding due to tramadol excretion. Adjust dose in renal impairment (Cr Cl <30 m L/min: extended interval). Discontinue gradually to avoid withdrawal.
Butabarbital is a short-acting barbiturate with a rapid onset; monitor for respiratory depression, especially when combined with other CNS depressants. Use with caution in hepatic impairment due to prolonged half-life. Tolerance and dependence develop with prolonged use; abrupt discontinuation may precipitate withdrawal seizures. Barbiturates induce CYP450 enzymes, potentially reducing efficacy of oral contraceptives, warfarin, and corticosteroids.
Do not exceed 8 tablets per day due to acetaminophen liver risk.,Avoid alcohol and other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until effect known.,Report signs of serotonin syndrome (agitation, hallucinations, rapid heart rate).,Do not stop suddenly; taper to prevent withdrawal symptoms.,Store at room temperature away from moisture.,Use only as prescribed; risk of dependence with tramadol.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may cause severe sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Do not stop taking abruptly; withdrawal can cause anxiety, tremors, and seizures. Taper under medical supervision.,This medication may be habit-forming; store in a safe place to prevent misuse.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Inform your doctor of all medications you take, including herbal supplements and over-the-counter drugs.
No interactions on record
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLZITAL vs BUTABARB, answered by our medical review team.
ALLZITAL is a Barbiturate Analgesic Combination that works by Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.. BUTABARB is a Barbiturate that works by Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLZITAL and BUTABARB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLZITAL is: 5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.. The standard adult dose of BUTABARB is: 15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLZITAL and BUTABARB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLZITAL is classified as Category C. Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbitu. BUTABARB is classified as Category C. Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.